A new study published in the journal of BMC Pulmonary Medicine showed that 10% of psoriasis patients would have interstitial ...

Secukinumab is under clinical development by Novartis and currently in Phase II for Coronavirus Disease 2019 (COVID-19) Pneumonia.

Zasocitinib is under clinical development by Takeda Pharmaceutical and currently in Phase I for Systemic Lupus Erythematosus.

German drugmaker Boehringer Ingelheim has its first regulatory approval for spesolimab, its antibody therapy for rare and life-threatening skin disorder generalised pustular psoriasis (GPP), in ...

There is no known way to prevent genital psoriasis from developing in the first place. You may be able to prevent flares, which are times when the disease is active and symptoms are present.

Other potential disease targets include palmoplantar pustulosis, generalised pustular psoriasis and pyoderma gangrenosum. Several further phase 2 trials are planned soon, the company said.

Sep. 26, 2024 — Scientists believe the hormone hepcidin, when produced in the skin, may be the root cause of psoriasis -- a chronic and sometimes debilitating skin disease that affects 2-3% of ...

Tildrakizumab was well tolerated and achieved sustained response in patients with moderate to severe plaque psoriasis of the scalp in a phase 3 study. This study excluded patients with ...

AI-Enabled Analysis of Images Meant to Catch One Disease Can Reveal Others Dec. 4, 2024 — With the help of an AI tool, computed tomography (CT) scans taken originally to look for tumors or ...

If there are no fungal spores, it can reasonably be assumed that psoriasis is the cause. Systemic lupus erythematosus, also known as lupus, is an autoimmune disease that affects multiple organ systems ...

Psoriasis is a chronic, relapsing, inflammatory skin and joint disease. Psoriasis affects 1%-3% of the US population. [1] Its effect on physical appearance greatly affects patients' quality of life.